Fudan University — Biomedical Watch V2

Traitements11programmes

Essais4liés

Publications0liées

SourceDBlocale

Traitements

11

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
1-week PBIThis non-inferiority, phase 3 clinical trial evaluates the cosmetic non-inferiority of a one-week regimen (26 Gy/5 Fx) versus a three-week regimen (40 Gy/15 Fx) using intensity-modulated radiation therapy (IMRT) for partial breast irradiation (PBI) in low-risk breast cancer patients post-breast-conserving surgery. It also compares secondary outcomes including efficacy, safety, and quality of life between the two groups.	Cancer	Non applicable	À vérifier	China	À vérifier
3-week PBIThis non-inferiority, phase 3 clinical trial evaluates the cosmetic non-inferiority of a one-week regimen (26 Gy/5 Fx) versus a three-week regimen (40 Gy/15 Fx) using intensity-modulated radiation therapy (IMRT) for partial breast irradiation (PBI) in low-risk breast cancer patients post-breast-conserving surgery. It also compares secondary outcomes including efficacy, safety, and quality of life between the two groups.	Cancer	Non applicable	À vérifier	China	À vérifier
Disease-Modifying TherapyThe goal of this multicenter retrospective observational study is to learn about the real-world safety and clinical effectiveness of disease-modifying therapy (DMT) in adults with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or AD dementia. The main questions it aims to answer are: What are the safety outcomes of DMT, including amyloid-related imaging abnormalities (ARIA), adverse events, and infusion reactions (IRRs)? How do Clinical Dementia Rating (CDR) measures change in patients who receive DMT compared with those who do not? Researchers will compare patients who receive DMT as part of their routine clinical care with patients who do not receive DMT to evaluate differences in clinical outcomes and safety. Participants will not receive any study-assigned intervention or additional treatment as part of this study. Researchers will retrospectively collect existing clinical data, including cognitive and neuropsychiatric assessments, imaging findings, biomarker results, DMT use, and safety information.	Alzheimer	À vérifier	À vérifier	China	À vérifier
imotuzumab combined with the NALIRIFOX chemotherapyThis is a prospective, single-arm study in patients with locally advanced or metastatic pancreatic cancer that cannot be treated with surgery. The study is planned to enroll 42 patients. All patients will receive nimotuzumab combined with the NALIRIFOX chemotherapy regimen as first-line treatment. Nimotuzumab is a targeted antibody against EGFR. NALIRIFOX is a standard first-line chemotherapy regimen for advanced pancreatic cancer and includes liposomal irinotecan, oxaliplatin, leucovorin, and 5-FU. Nimotuzumab 400 mg will be given intravenously on Day 1 every 2 weeks. The NALIRIFOX regimen will also be given every 2 weeks. Treatment will continue until the cancer grows or the side effects become unacceptable. The main purpose of this study is to find out how long patients live without their cancer getting worse (progression-free survival, PFS). The study will also look at overall survival, tumor response rate, disease control rate, time to progression, and safety, especially serious side effects. Patients will be followed closely during treatment. Imaging tests will be done every 8 weeks to check the cancer. After treatment ends, patients will be followed for survival for up to 24 months after the last patient is enrolled.	Cancer	Phase 2	Ralentissement de la progression	China	À vérifier
MTT(Multimodal Tumor Thermal Therapy System)- Colorectal CancerThis study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma. Currently, there are limitations in the treatment of liver metastases of these cancers. Multimodal thermophysical ablation therapy can reshape the tumor microenvironment, release neoantigens, and act as an in-situ vaccine. On this basis, the combination of multimodal ablation with immunotherapeutic drugs such as pucotenlimab will be explored. The efficacy and safety of this combination therapy in patients with liver metastases of solid tumors will be investigated, with the expectation of breaking through the existing treatment limitations.	Cancer	Phase 2	À vérifier	China	À vérifier
MTT(Multimodal Tumor Thermal Therapy System)- MelanomaThis study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma. Currently, there are limitations in the treatment of liver metastases of these cancers. Multimodal thermophysical ablation therapy can reshape the tumor microenvironment, release neoantigens, and act as an in-situ vaccine. On this basis, the combination of multimodal ablation with immunotherapeutic drugs such as pucotenlimab will be explored. The efficacy and safety of this combination therapy in patients with liver metastases of solid tumors will be investigated, with the expectation of breaking through the existing treatment limitations.	Cancer	Phase 2	À vérifier	China	À vérifier
MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast CancerThis study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma. Currently, there are limitations in the treatment of liver metastases of these cancers. Multimodal thermophysical ablation therapy can reshape the tumor microenvironment, release neoantigens, and act as an in-situ vaccine. On this basis, the combination of multimodal ablation with immunotherapeutic drugs such as pucotenlimab will be explored. The efficacy and safety of this combination therapy in patients with liver metastases of solid tumors will be investigated, with the expectation of breaking through the existing treatment limitations.	Cancer	Phase 2	À vérifier	China	À vérifier
3-week PBIThis non-inferiority, phase 3 clinical trial evaluates the cosmetic non-inferiority of a one-week regimen (26 Gy/5 Fx) versus a three-week regimen (40 Gy/15 Fx) using intensity-modulated radiation therapy (IMRT) for partial breast irradiation (PBI) in low-risk breast cancer patients post-breast-conserving surgery. It also compares secondary outcomes including efficacy, safety, and quality of life between the two groups.	Cancer	Non applicable	À vérifier	China	À vérifier
MTT(Multimodal Tumor Thermal Therapy System)- Colorectal CancerThis study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma. Currently, there are limitations in the treatment of liver metastases of these cancers. Multimodal thermophysical ablation therapy can reshape the tumor microenvironment, release neoantigens, and act as an in-situ vaccine. On this basis, the combination of multimodal ablation with immunotherapeutic drugs such as pucotenlimab will be explored. The efficacy and safety of this combination therapy in patients with liver metastases of solid tumors will be investigated, with the expectation of breaking through the existing treatment limitations.	Cancer	Phase 2	À vérifier	China	À vérifier
Disease-Modifying TherapyThe goal of this multicenter retrospective observational study is to learn about the real-world safety and clinical effectiveness of disease-modifying therapy (DMT) in adults with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or AD dementia. The main questions it aims to answer are: What are the safety outcomes of DMT, including amyloid-related imaging abnormalities (ARIA), adverse events, and infusion reactions (IRRs)? How do Clinical Dementia Rating (CDR) measures change in patients who receive DMT compared with those who do not? Researchers will compare patients who receive DMT as part of their routine clinical care with patients who do not receive DMT to evaluate differences in clinical outcomes and safety. Participants will not receive any study-assigned intervention or additional treatment as part of this study. Researchers will retrospectively collect existing clinical data, including cognitive and neuropsychiatric assessments, imaging findings, biomarker results, DMT use, and safety information.	Alzheimer	À vérifier	À vérifier	China	À vérifier
imotuzumab combined with the NALIRIFOX chemotherapyThis is a prospective, single-arm study in patients with locally advanced or metastatic pancreatic cancer that cannot be treated with surgery. The study is planned to enroll 42 patients. All patients will receive nimotuzumab combined with the NALIRIFOX chemotherapy regimen as first-line treatment. Nimotuzumab is a targeted antibody against EGFR. NALIRIFOX is a standard first-line chemotherapy regimen for advanced pancreatic cancer and includes liposomal irinotecan, oxaliplatin, leucovorin, and 5-FU. Nimotuzumab 400 mg will be given intravenously on Day 1 every 2 weeks. The NALIRIFOX regimen will also be given every 2 weeks. Treatment will continue until the cancer grows or the side effects become unacceptable. The main purpose of this study is to find out how long patients live without their cancer getting worse (progression-free survival, PFS). The study will also look at overall survival, tumor response rate, disease control rate, time to progression, and safety, especially serious side effects. Patients will be followed closely during treatment. Imaging tests will be done every 8 weeks to check the cancer. After treatment ends, patients will be followed for survival for up to 24 months after the last patient is enrolled.	Cancer	Phase 2	Ralentissement de la progression	China	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
imotuzumab combined with the NALIRIFOX chemotherapy	Cancer	Phase 2	NCT07920731	A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer	ENROLLING_BY_INVITATION
Disease-Modifying Therapy	Alzheimer	À vérifier	NCT07923812	ROOT-AD — Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study	RECRUITING
MTT(Multimodal Tumor Thermal Therapy System)- Colorectal Cancer	Cancer	Phase 2	NCT06889610	A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.	RECRUITING
3-week PBI	Cancer	Non applicable	NCT07814365	PBI for Low-risk Breast Cancer	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.